CollPlant to Report 2025 Financial Results on March 26, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2026
0mins
Should l Buy CLGN?
Source: PRnewswire
- Earnings Report Schedule: CollPlant Biotechnologies plans to release its financial results for the fiscal year 2025 on March 26, 2026, before the U.S. market opens, which is expected to provide crucial insights into the company's financial health and may influence its stock performance.
- Technological Innovation Focus: CollPlant specializes in regenerative and aesthetic products based on non-animal-derived collagen, utilizing its proprietary plant-based genetic engineering technology to produce recombinant human collagen, aiming to meet diverse needs in tissue repair and aesthetics while driving technological advancements in the industry.
- Strategic Partnership: In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, a leader in the dermal filler market, which not only strengthens CollPlant's market position but also lays the groundwork for future revenue growth.
- Company Vision: CollPlant is committed to advancing the manufacturing of tissues and organs through 3D bioprinting technology, marking a new era of medical solutions that is expected to have a profound impact on the field of regenerative medicine and enhance the company's competitiveness in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLGN
About CLGN
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CollPlant to Report 2025 Financial Results on March 26, 2026
- Earnings Report Schedule: CollPlant Biotechnologies plans to release its financial results for the fiscal year 2025 on March 26, 2026, before the U.S. market opens, which is expected to provide crucial insights into the company's financial health and may influence its stock performance.
- Technological Innovation Focus: CollPlant specializes in regenerative and aesthetic products based on non-animal-derived collagen, utilizing its proprietary plant-based genetic engineering technology to produce recombinant human collagen, aiming to meet diverse needs in tissue repair and aesthetics while driving technological advancements in the industry.
- Strategic Partnership: In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, a leader in the dermal filler market, which not only strengthens CollPlant's market position but also lays the groundwork for future revenue growth.
- Company Vision: CollPlant is committed to advancing the manufacturing of tissues and organs through 3D bioprinting technology, marking a new era of medical solutions that is expected to have a profound impact on the field of regenerative medicine and enhance the company's competitiveness in the industry.
See More
CollPlant Launches BioFlex Bioink Kit for 3D Bioprinting
- BioFlex Product Launch: CollPlant has introduced the BioFlex bioink kit, based on recombinant human collagen, designed to support Digital Light Processing (DLP) 3D bioprinting, advancing drug discovery and tissue engineering.
- Technological Innovation: The BioFlex system integrates Collink.3D™ 50 biodegradable polymer and photoactive components, optimizing high-resolution printing and significantly enhancing the mechanical properties and structural integrity of bioinks.
- Market Applications: This product is suitable for both academic laboratories and industrial R&D, facilitating faster translation in 3D bioprinting and regenerative medicine, thereby shortening product development cycles.
- Strategic Importance: CollPlant CEO Yehiel Tal stated that BioFlex will streamline the formulation process, reduce development costs, and provide an animal-free high-resolution printing solution, supporting innovation in biopharma and academic research.
See More
CollPlant Launches BioFlex Bioink for Advanced 3D Bioprinting
- BioFlex Product Launch: CollPlant has introduced the BioFlex bioink kit, specifically designed for Digital Light Processing (DLP) 3D bioprinting applications, aimed at supporting biofabrication for drug discovery and engineered tissues, marking a significant technological advancement in regenerative medicine.
- High-Performance Features: The BioFlex system integrates Collink.3D™ 50 biodegradable polymer with optimized photoactive components, enabling users to efficiently generate bioinks with tunable mechanical properties, thereby facilitating the precise fabrication of complex biological structures and enhancing applications in tissue engineering.
- Reduced Development Time: By streamlining the formulation development process, BioFlex significantly shortens R&D timelines, allowing researchers and industry partners to quickly achieve high-resolution printing outcomes, thus promoting faster translation from concept to functional tissue constructs.
- Market Competitive Advantage: As an animal-free alternative, BioFlex offers high-resolution, scalable, and highly reproducible bioprinting solutions, helping CollPlant secure a leading position in the fields of regenerative medicine and tissue engineering while reducing overall development costs and accelerating innovation timelines.
See More
Wall Street Analysts Adjust Ratings on Top Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market views and expectations for these companies.
- Market Reaction: While specific stocks were not mentioned, such rating changes typically influence investor decisions and may lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying PI stock should pay attention to analysts' opinions to better assess potential investment risks and returns.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, especially in a rapidly changing market environment.
See More
D. Boral Capital Upholds Buy Rating for CollPlant Biotechnologies (CLGN)
Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for CollPlant Biotechnologies, with a projected one-year price target of $11.73/share, indicating a potential upside of 436.16% from its current price of $2.19/share.
Projected Revenue and EPS: CollPlant Biotechnologies is expected to see a significant increase in annual revenue, projected at $5,277 million, alongside a non-GAAP EPS forecast of 6.62.
Fund Sentiment: There has been a slight increase in institutional ownership, with 17 funds reporting positions in CollPlant, although total shares owned by institutions decreased by 19.63% over the last three months.
Shareholder Activity: Notable shareholders like Villere St Denis J & Co and AMH Equity have increased their holdings in CollPlant, while Renaissance Technologies has significantly reduced its stake.
See More
D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies with $12 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
See More
CollPlant to Report 2025 Financial Results on March 26, 2026
- Earnings Report Schedule: CollPlant Biotechnologies plans to release its financial results for the fiscal year 2025 on March 26, 2026, before the U.S. market opens, which is expected to provide crucial insights into the company's financial health and may influence its stock performance.
- Technological Innovation Focus: CollPlant specializes in regenerative and aesthetic products based on non-animal-derived collagen, utilizing its proprietary plant-based genetic engineering technology to produce recombinant human collagen, aiming to meet diverse needs in tissue repair and aesthetics while driving technological advancements in the industry.
- Strategic Partnership: In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, a leader in the dermal filler market, which not only strengthens CollPlant's market position but also lays the groundwork for future revenue growth.
- Company Vision: CollPlant is committed to advancing the manufacturing of tissues and organs through 3D bioprinting technology, marking a new era of medical solutions that is expected to have a profound impact on the field of regenerative medicine and enhance the company's competitiveness in the industry.
See More
CollPlant Launches BioFlex Bioink Kit for 3D Bioprinting
- BioFlex Product Launch: CollPlant has introduced the BioFlex bioink kit, based on recombinant human collagen, designed to support Digital Light Processing (DLP) 3D bioprinting, advancing drug discovery and tissue engineering.
- Technological Innovation: The BioFlex system integrates Collink.3D™ 50 biodegradable polymer and photoactive components, optimizing high-resolution printing and significantly enhancing the mechanical properties and structural integrity of bioinks.
- Market Applications: This product is suitable for both academic laboratories and industrial R&D, facilitating faster translation in 3D bioprinting and regenerative medicine, thereby shortening product development cycles.
- Strategic Importance: CollPlant CEO Yehiel Tal stated that BioFlex will streamline the formulation process, reduce development costs, and provide an animal-free high-resolution printing solution, supporting innovation in biopharma and academic research.
See More
CollPlant Launches BioFlex Bioink for Advanced 3D Bioprinting
- BioFlex Product Launch: CollPlant has introduced the BioFlex bioink kit, specifically designed for Digital Light Processing (DLP) 3D bioprinting applications, aimed at supporting biofabrication for drug discovery and engineered tissues, marking a significant technological advancement in regenerative medicine.
- High-Performance Features: The BioFlex system integrates Collink.3D™ 50 biodegradable polymer with optimized photoactive components, enabling users to efficiently generate bioinks with tunable mechanical properties, thereby facilitating the precise fabrication of complex biological structures and enhancing applications in tissue engineering.
- Reduced Development Time: By streamlining the formulation development process, BioFlex significantly shortens R&D timelines, allowing researchers and industry partners to quickly achieve high-resolution printing outcomes, thus promoting faster translation from concept to functional tissue constructs.
- Market Competitive Advantage: As an animal-free alternative, BioFlex offers high-resolution, scalable, and highly reproducible bioprinting solutions, helping CollPlant secure a leading position in the fields of regenerative medicine and tissue engineering while reducing overall development costs and accelerating innovation timelines.
See More
Wall Street Analysts Adjust Ratings on Top Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting the latest market views and expectations for these companies.
- Market Reaction: While specific stocks were not mentioned, such rating changes typically influence investor decisions and may lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying PI stock should pay attention to analysts' opinions to better assess potential investment risks and returns.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, especially in a rapidly changing market environment.
See More
D. Boral Capital Upholds Buy Rating for CollPlant Biotechnologies (CLGN)
Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for CollPlant Biotechnologies, with a projected one-year price target of $11.73/share, indicating a potential upside of 436.16% from its current price of $2.19/share.
Projected Revenue and EPS: CollPlant Biotechnologies is expected to see a significant increase in annual revenue, projected at $5,277 million, alongside a non-GAAP EPS forecast of 6.62.
Fund Sentiment: There has been a slight increase in institutional ownership, with 17 funds reporting positions in CollPlant, although total shares owned by institutions decreased by 19.63% over the last three months.
Shareholder Activity: Notable shareholders like Villere St Denis J & Co and AMH Equity have increased their holdings in CollPlant, while Renaissance Technologies has significantly reduced its stake.
See More
D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies with $12 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
See More
